Medically reviewed by Drugs.com. Last updated on Oct 31, 2019.
Applies to the following strengths: dbll 6 mg/0.05 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Macular Degeneration
Initial dose: 6 mg by intravitreal injection once a month for the first 3 doses
Maintenance dose: 6 mg by intravitreal injection once every 8 to 12 weeks
-This drug should be administered by a qualified physician.
-Once monthly injections should be administered approximately every 25 to 31 days.
-In clinical trials, the maintenance dosing interval was guided by visual and anatomical measures of disease activity; the utility of these measures has not been established.
Use: For the treatment of neovascular (wet) age-related macular degeneration (AMD).
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended
-Patients with ocular or periocular infections
-Patients with active intraocular inflammation
-Hypersensitivity to the active drug or any product excipients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be administered by a qualified physician
-This drug is for ophthalmic intravitreal injection only
-Adequate anesthesia and a broad-spectrum topical microbicide should be used to disinfect prior to injection
-Store refrigerated 2C to 8C (36F to 46F); do not freeze
-Prior to use, keep in outer carton to protect from light
-Prior to use, the unopened vial may be kept at room temperature 20C to 25C (68F to 77F) for up to 24 hours
-Kit includes drug in a sterile glass vial and sterile filter needle (5-micron blunt filter needle [18-gauge x 1½ inch, 1.2 mm x 40 mm])
-For injection, will need a sterile 30-gauge x ½ inch injection needle and sterile 1 mL syringe with a 0.05 mL dose mark
-Injection should occur immediately after dose preparation; the product labeling may be consulted for injection procedure
-A single vial should be used to treat a single eye; if the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before administration to the other eye.
-Following injection, monitor intraocular pressure and check perfusion of the optic nerve head or tonometry
-Patients should understand that in the days following injection, there is a risk of developing endophthalmitis; if their eye becomes red, sensitive to light, painful, or there are visual changes, they should seek immediate care from an ophthalmologist.
-Patients should understand that they may experience temporary visual disturbances; patients should be advised not to drive or use machinery until visual function has sufficiently recovered.
Frequently asked questions
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about brolucizumab
- Side Effects
- During Pregnancy or Breastfeeding
- Patient Tips
- En Español
- 1 Review
- Drug class: anti-angiogenic ophthalmic agents
Other brands: Beovu